Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00436137
Status:
COMPLETED
Last Update Posted:
2008-11-06
First Post:
2007-02-14
Brief Title:
Improving Followup of Abnormal Colon Cancer Screening Tests
Sponsor:
Harvard Vanguard Medical Associates
Organization:
Harvard Vanguard Medical Associates
Study Overview
Official Title:
Improving Followup of Positive Fecal Occult Blood Tests
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether direct mailings to patients with positive fecal occult blood tests can increase rates of performing followup colonoscopy
Detailed Description:
Screening programs using the fecal occult blood test FOBT have demonstrated a significant reduction in colorectal cancer mortality although only when accompanied by a complete diagnostic evaluation of the colon in the setting of a positive result 90 of patients with a positive FOBT result have completed a subsequent colonoscopy within Harvard Vanguard Medical Associates This project will use a pre-post study design to increase the rate of followup colonoscopy in the setting of positive FOBT results Patients in the intervention group will receive a personalized mailing highlighting their positive result and need for colonoscopy followed by telephone outreach from a centralized gastroenterology scheduling office The primary outcome will be the performance of colonoscopy however we will also perform chart reviews to identify predictors of completing appropriate followup
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None